^
    Back
    Association details:
    Biomarker:PTEN R130del
    Cancer:Thyroid Gland Papillary Carcinoma
    Drug:MK-2206 (AKT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    J Clin Endocrinol Metab
    Title:

    The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway

    Excerpt:
    Thyroid cancer cells OCUT1, K1, FTC133, C643, Hth7, and TPC1 harbored PIK3CA, PTEN, Ras, or RET/PTC mutations that could activate the PI3K/Akt pathway. MK2206 inhibited the proliferation of all these cells with IC50 values in the low micromolar range, mostly below or around 0.5 μm....Genotypes of thyroid cell lines and their sensitivities to MK2206.
    DOI:
    10.1210/jc.2010-2644